Thymosin alpha-1Immunomodulatory peptide
Thymosin alpha-1, also called thymalfasin, has been studied in several infectious and immune settings. The clearest interpretation separates each disease and keeps larger controlled results beside earlier positive reports.
What is Thymosin alpha-1?
Thymosin alpha-1 is a thymus-associated peptide studied for immune regulation in conditions including viral infection and sepsis.
How it works
Research examines its effects on several immune-cell functions. The intended immune response differs across diseases, so there is no single established “immune support” outcome.
Effects studied
Sepsis mortality
TESTS analysed 1,089 treated adults. Day-28 mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo, a difference that was not statistically significant. 1
Evidence: Large controlled trial that did not establish a mortality reduction in the studied population.
What does the evidence show?
Condition-specific trials; TESTS sepsis study checked
A broad research history
Thymosin alpha-1 is a peptide associated with thymic biology and immune regulation. Researchers have explored effects on several immune-cell functions. This has led to studies in very different situations, including chronic viral infection and sepsis, where the desired change in immunity is not necessarily the same.
A large sepsis study adds perspective
The TESTS trial analysed 1,089 treated adults with sepsis. Death by day 28 occurred in 23.4% of the thymosin group and 24.1% of the placebo group. The difference was not statistically significant, and the study did not establish reduced mortality. 1
Why earlier enthusiasm is not enough
Smaller studies had suggested benefit, which the larger controlled trial tested more rigorously. Exploratory subgroup findings may inform further research, but cannot replace the overall result or establish benefit in an untested population.
The disease-specific question remains
Evidence in hepatitis cannot establish that healthy people get fewer respiratory infections, just as a sepsis trial cannot settle every immune indication. Product quality, route and jurisdiction also matter. The relevant question is which clinical outcome improved, and in whom. “Immune support” is too imprecise to answer it.
Safety & status
Product identity, route and clinical condition matter. A sepsis or hepatitis study does not establish the benefit–risk balance for use by healthy people.
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Did the large sepsis trial reduce deaths?
It did not establish a statistically significant mortality reduction. 1
Can evidence in hepatitis establish fewer colds in healthy people?
No. Those are different populations, diseases and clinical outcomes.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- BMJ · TESTS phase 3 trial of thymosin alpha-1 in sepsis Primary randomised trial · Abstract and reported primary results checked 27 October 2026; no comprehensive review of all indications.
- Thymosin alpha-1 · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Thymosin alpha-1 · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.